Skip to content
Scientist in safety glasses loading a grinding jar into a mixer mill inside its enclosure

TeraCrystal — Beyond the crystal

Your API is chemically pure.Is it development-ready?

Turning solid-state complexity into actionable pharmaceutical development insights.

46.77° N · 23.59° E — CLUJ-NAPOCA

Areas of specialist support
5
Published research stories
6
Crystal size resolved in published structure work
~500nm
Span of cited peer-reviewed studies
2018–2026

Chemical purity is only one part of pharmaceutical development. The solid form of an active pharmaceutical ingredient can influence how a material behaves during processing, formulation and storage. Polymorphism, phase transformations, crystal structure and crystallization behavior can therefore become critical development questions. TeraCrystal helps teams investigate these questions and turn complex solid-state findings into practical development insights.

Gloved hands clamping a steel grinding jar into an MM 400 mixer mill, seen from above

01 — Who we are

Who We Are

TeraCrystal is a specialized scientific partner for pharmaceutical solid-state chemistry, crystallography, crystal engineering and crystallization development. We combine structural understanding with targeted experimental investigations to help pharmaceutical companies, biotechnology teams and development partners address questions that are not answered by chemical identity or purity alone. Our focus is to connect scientific evidence with decisions about solid-form selection, phase identification, crystallization and downstream development.

Through collaboration with Dr. Matthias Gerlach, we also help clients connect scientific findings with wider CMC development, regulatory and manufacturing decisions.

Our Vision

Our Vision

To make solid-state complexity a manageable part of pharmaceutical innovation rather than a barrier to successful development.

Our Mission

Our Mission

We help pharmaceutical and development partners understand, select and control solid forms through advanced structural science, targeted experimentation and crystallization expertise.

02 — Our strategy

Our Strategy

Establish TeraCrystal as a recognized specialist for complex solid-state and crystallization challenges through scientific differentiation, clearly defined services, evidence-based credibility and targeted partnerships.

Four Pillars of Our Strategy

  1. 01

    Scientific Specialization

    Focus on complex structural, solid-form and crystallization questions where specialist insight can materially inform development decisions.

  2. 02

    Commercially Defined Services

    Organize our expertise around clearly scoped investigations, agreed scientific questions and useful development outputs.

  3. 03

    Evidence-Based Credibility

    Connect our scientific capabilities to attributable publications, patents and approved examples, while distinguishing research evidence from individual commercial project claims.

  4. 04

    Partnership-Driven Growth

    Collaborate with pharmaceutical and biotech teams, API manufacturers, dosage-form CDMOs and complementary scientific specialists.

Fume hood bench set up with pipettes, coloured sample vials, a separatory funnel and a flask on a stirring hotplate

Beyond the crystal.

03 — Challenges

Where Solid-State Questions Become Development Challenges

These are the questions we help teams investigate with a scientific approach tailored to the material and the decision at hand.

  1. Which solid form should be developed?

  2. Can an unexpected phase be identified reliably?

  3. Could a transformation occur during crystallization, processing or storage?

  4. What do material properties mean for the next development step?

05 — Scientific evidence

Science Behind the Decisions

Our scientific foundation includes work in crystallography, crystal engineering, solid-form investigations and crystallization. Selected research topics include structure determination from very small crystals, salt-versus-co-crystal questions, phase transformations and formulation-relevant material behavior. We present these studies with their original attribution and explain what they can—and cannot—tell development teams.

  • Structure from very small crystals
  • Salt vs. co-crystal
  • Phase transformations
  • Formulation-relevant behavior

Published, study-specific findings. Not a performance guarantee.

06 — Partnerships

Working Across the Development Ecosystem

We work with the questions faced by pharmaceutical and biotech developers, API manufacturers, oral solid dosage-form developers and semisolid formulation teams. Our role is to contribute specialist scientific understanding to the wider development effort, with project scope and responsibilities defined for each collaboration.

  1. 01Pharma & biotech developers
  2. 02API manufacturers
  3. 03Oral solid dosage-form developers
  4. 04Semisolid formulation teams

07 — Reach

From Cluj-Napoca to development teams across borders

TeraCrystal works from its laboratory in Cluj-Napoca with partners and scientific collaborators in Europe and beyond.

PREVIEW DATA — TO BE CONFIRMED

  • LaboratoryCluj-Napoca, RomaniaHeadquarters and laboratory
  • PartnershipSwitzerlandElectron diffraction partnership
  • Scientific communityBologna, ItalyConvention on crystal forms
  • Scientific communityBrussels, BelgiumCrystal growth of organic materials conference
  • Scientific communityZagreb, CroatiaCOST Action meeting
  • ClientsUnited StatesPharmaceutical and biotech teams

Discuss Your Challenge

An unexpected solid form, an unresolved structure or a crystallization question may require a focused scientific investigation. Tell us what you know about the material, what remains uncertain and which development decision you need to make. We can discuss a suitable next step and the information needed to scope an investigation.

Scientist in safety glasses operating a freeze-dryer with glass sample vials on its shelves